APO Research
Talk to an analyst

APO RESEARCH · REPORT

Rare Disease Therapy Solutions

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Rare Disease Therapy Solutions Market Analysis and Forecast 2026-2032

4 January 2026193 pages

Choose your research edition.

Industry ResearchRare Disease Therapy Solutions Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Rare Disease Therapy Solutions Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Rare Disease Therapy Solutions Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rare Disease Therapy Solutions Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Rare Disease Therapy Solutions Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Rare Disease Therapy Solutions market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Rare Disease Therapy Solutions is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Rare Disease Therapy Solutions is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Rare Disease Therapy Solutions is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Rare Disease Therapy Solutions is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Rare Disease Therapy Solutions include Sarepta, Ultragenyx, Amicus Therapeutics, AOP Health, Fortrea, Chiesi Global Rare Diseases, Travere Therapeutics, Sobi and Novartis, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Rare Disease Therapy Solutions, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Rare Disease Therapy Solutions, also provides the revenue of main regions and countries. Of the upcoming market potential for Rare Disease Therapy Solutions, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Rare Disease Therapy Solutions revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Rare Disease Therapy Solutions market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Rare Disease Therapy Solutions revenue, projected growth trends, production technology, application and end-user industry.

Rare Disease Therapy Solutions Segment by Company

Sarepta

Ultragenyx

Amicus Therapeutics

AOP Health

Fortrea

Chiesi Global Rare Diseases

Travere Therapeutics

Sobi

Novartis

Vertex Pharmaceuticals

Sarepta International UK Ltd.

Orsini

Roche

Certara

Sciensus

Rare Disease Therapy Solutions Segment by Type

Gene Therapy

Enzyme Replacement Therapy

Small Molecule Targeted Drugs

Cell Therapy

Others

Rare Disease Therapy Solutions Segment by Application

Metabolic Diseases

Hematological Diseases

Others

Rare Disease Therapy Solutions Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rare Disease Therapy Solutions market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rare Disease Therapy Solutions and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rare Disease Therapy Solutions.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Rare Disease Therapy Solutions in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Rare Disease Therapy Solutions company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Rare Disease Therapy Solutions revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Rare Disease Therapy Solutions Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Gene Therapy Major Player Table 3. Enzyme Replacement Therapy Major Player Table 4. Small Molecule Targeted Drugs Major Player Table 5. Cell Therapy Major Player Table 6. Others Major Player Table 7. Global Rare Disease Therapy Solutions Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Metabolic Diseases Major Player Table 9. Hematological Diseases Major Player Table 10. Others Major Player Table 11. Rare Disease Therapy Solutions Industry Trends Table 12. Rare Disease Therapy Solutions Industry Drivers Table 13. Rare Disease Therapy Solutions Industry Opportunities and Challenges Table 14. Rare Disease Therapy Solutions Industry Restraints Table 15. Global Rare Disease Therapy Solutions Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Rare Disease Therapy Solutions Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Rare Disease Therapy Solutions Market Share by Region (2021-2026) Table 18. Global Rare Disease Therapy Solutions Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Rare Disease Therapy Solutions Market Share by Region (2027-2032) Table 20. Global Rare Disease Therapy Solutions Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Rare Disease Therapy Solutions Revenue Market Share by Players (2021-2026) Table 22. Global Rare Disease Therapy Solutions Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Rare Disease Therapy Solutions Key Players Headquarters & Area Served Table 24. Global Rare Disease Therapy Solutions Players, Product Type & Application Table 25. Global Rare Disease Therapy Solutions Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Rare Disease Therapy Solutions by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Rare Disease Therapy Solutions Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Rare Disease Therapy Solutions Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Rare Disease Therapy Solutions Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Rare Disease Therapy Solutions Revenue Market Share by Type (2021-2026) Table 32. Global Rare Disease Therapy Solutions Revenue Market Share by Type (2027-2032) Table 33. Global Rare Disease Therapy Solutions Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Rare Disease Therapy Solutions Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Rare Disease Therapy Solutions Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Rare Disease Therapy Solutions Revenue Market Share by Application (2021-2026) Table 37. Global Rare Disease Therapy Solutions Revenue Market Share by Application (2027-2032) Table 38. Sarepta Company Information Table 39. Sarepta Business Overview Table 40. Sarepta Rare Disease Therapy Solutions Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Sarepta Rare Disease Therapy Solutions Product Portfolio Table 42. Sarepta Recent Development Table 43. Ultragenyx Company Information Table 44. Ultragenyx Business Overview Table 45. Ultragenyx Rare Disease Therapy Solutions Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Ultragenyx Rare Disease Therapy Solutions Product Portfolio Table 47. Ultragenyx Recent Development Table 48. Amicus Therapeutics Company Information Table 49. Amicus Therapeutics Business Overview Table 50. Amicus Therapeutics Rare Disease Therapy Solutions Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Amicus Therapeutics Rare Disease Therapy Solutions Product Portfolio Table 52. Amicus Therapeutics Recent Development Table 53. AOP Health Company Information Table 54. AOP Health Business Overview Table 55. AOP Health Rare Disease Therapy Solutions Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. AOP Health Rare Disease Therapy Solutions Product Portfolio Table 57. AOP Health Recent Development Table 58. Fortrea Company Information Table 59. Fortrea Business Overview Table 60. Fortrea Rare Disease Therapy Solutions Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Fortrea Rare Disease Therapy Solutions Product Portfolio Table 62. Fortrea Recent Development Table 63. Chiesi Global Rare Diseases Company Information Table 64. Chiesi Global Rare Diseases Business Overview Table 65. Chiesi Global Rare Diseases Rare Disease Therapy Solutions Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Chiesi Global Rare Diseases Rare Disease Therapy Solutions Product Portfolio Table 67. Chiesi Global Rare Diseases Recent Development Table 68. Travere Therapeutics Company Information Table 69. Travere Therapeutics Business Overview Table 70. Travere Therapeutics Rare Disease Therapy Solutions Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Travere Therapeutics Rare Disease Therapy Solutions Product Portfolio Table 72. Travere Therapeutics Recent Development Table 73. Sobi Company Information Table 74. Sobi Business Overview Table 75. Sobi Rare Disease Therapy Solutions Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Sobi Rare Disease Therapy Solutions Product Portfolio Table 77. Sobi Recent Development Table 78. Novartis Company Information Table 79. Novartis Business Overview Table 80. Novartis Rare Disease Therapy Solutions Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Novartis Rare Disease Therapy Solutions Product Portfolio Table 82. Novartis Recent Development Table 83. Vertex Pharmaceuticals Company Information Table 84. Vertex Pharmaceuticals Business Overview Table 85. Vertex Pharmaceuticals Rare Disease Therapy Solutions Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Vertex Pharmaceuticals Rare Disease Therapy Solutions Product Portfolio Table 87. Vertex Pharmaceuticals Recent Development Table 88. Sarepta International UK Ltd. Company Information Table 89. Sarepta International UK Ltd. Business Overview Table 90. Sarepta International UK Ltd. Rare Disease Therapy Solutions Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Sarepta International UK Ltd. Rare Disease Therapy Solutions Product Portfolio Table 92. Sarepta International UK Ltd. Recent Development Table 93. Orsini Company Information Table 94. Orsini Business Overview Table 95. Orsini Rare Disease Therapy Solutions Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Orsini Rare Disease Therapy Solutions Product Portfolio Table 97. Orsini Recent Development Table 98. Roche Company Information Table 99. Roche Business Overview Table 100. Roche Rare Disease Therapy Solutions Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Roche Rare Disease Therapy Solutions Product Portfolio Table 102. Roche Recent Development Table 103. Certara Company Information Table 104. Certara Business Overview Table 105. Certara Rare Disease Therapy Solutions Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Certara Rare Disease Therapy Solutions Product Portfolio Table 107. Certara Recent Development Table 108. Sciensus Company Information Table 109. Sciensus Business Overview Table 110. Sciensus Rare Disease Therapy Solutions Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Sciensus Rare Disease Therapy Solutions Product Portfolio Table 112. Sciensus Recent Development Table 113. North America Rare Disease Therapy Solutions Revenue by Type (2021-2026) & (US$ Million) Table 114. North America Rare Disease Therapy Solutions Revenue by Type (2027-2032) & (US$ Million) Table 115. North America Rare Disease Therapy Solutions Revenue by Application (2021-2026) & (US$ Million) Table 116. North America Rare Disease Therapy Solutions Revenue by Application (2027-2032) & (US$ Million) Table 117. North America Rare Disease Therapy Solutions Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. North America Rare Disease Therapy Solutions Revenue by Country (2021-2026) & (US$ Million) Table 119. North America Rare Disease Therapy Solutions Revenue by Country (US$ Million) & (2027-2032) Table 120. Europe Rare Disease Therapy Solutions Revenue by Type (2021-2026) & (US$ Million) Table 121. Europe Rare Disease Therapy Solutions Revenue by Type (2027-2032) & (US$ Million) Table 122. Europe Rare Disease Therapy Solutions Revenue by Application (2021-2026) & (US$ Million) Table 123. Europe Rare Disease Therapy Solutions Revenue by Application (2027-2032) & (US$ Million) Table 124. Europe Rare Disease Therapy Solutions Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 125. Europe Rare Disease Therapy Solutions Revenue by Country (2021-2026) & (US$ Million) Table 126. Europe Rare Disease Therapy Solutions Revenue by Country (US$ Million) & (2027-2032) Table 127. China Rare Disease Therapy Solutions Revenue by Type (2021-2026) & (US$ Million) Table 128. China Rare Disease Therapy Solutions Revenue by Type (2027-2032) & (US$ Million) Table 129. China Rare Disease Therapy Solutions Revenue by Application (2021-2026) & (US$ Million) Table 130. China Rare Disease Therapy Solutions Revenue by Application (2027-2032) & (US$ Million) Table 131. Asia Rare Disease Therapy Solutions Revenue by Type (2021-2026) & (US$ Million) Table 132. Asia Rare Disease Therapy Solutions Revenue by Type (2027-2032) & (US$ Million) Table 133. Asia Rare Disease Therapy Solutions Revenue by Application (2021-2026) & (US$ Million) Table 134. Asia Rare Disease Therapy Solutions Revenue by Application (2027-2032) & (US$ Million) Table 135. Asia Rare Disease Therapy Solutions Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 136. Asia Rare Disease Therapy Solutions Revenue by Region (US$ Million) & (2021-2026) Table 137. Asia Rare Disease Therapy Solutions Revenue by Region (US$ Million) & (2027-2032) Table 138. SAMEA Rare Disease Therapy Solutions Revenue by Type (2021-2026) & (US$ Million) Table 139. SAMEA Rare Disease Therapy Solutions Revenue by Type (2027-2032) & (US$ Million) Table 140. SAMEA Rare Disease Therapy Solutions Revenue by Application (2021-2026) & (US$ Million) Table 141. SAMEA Rare Disease Therapy Solutions Revenue by Application (2027-2032) & (US$ Million) Table 142. SAMEA Rare Disease Therapy Solutions Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. SAMEA Rare Disease Therapy Solutions Revenue by Country (2021-2026) & (US$ Million) Table 144. SAMEA Rare Disease Therapy Solutions Revenue by Country (US$ Million) & (2027-2032) Table 145. Research Programs/Design for This Report Table 146. Authors List of This Report Table 147. Secondary Sources Table 148. Primary Sources List of Figures Figure 1. Rare Disease Therapy Solutions Image Figure 2. Global Rare Disease Therapy Solutions Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rare Disease Therapy Solutions Market Size Share 2021 VS 2025 VS 2032 Figure 4. Gene Therapy Image Figure 5. Enzyme Replacement Therapy Image Figure 6. Small Molecule Targeted Drugs Image Figure 7. Cell Therapy Image Figure 8. Others Image Figure 9. Global Rare Disease Therapy Solutions Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Rare Disease Therapy Solutions Market Size Share 2021 VS 2025 VS 2032 Figure 11. Metabolic Diseases Image Figure 12. Hematological Diseases Image Figure 13. Others Image Figure 14. Global Rare Disease Therapy Solutions Market Size (US$ Million) & (2021-2032) Figure 15. Global Rare Disease Therapy Solutions Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Rare Disease Therapy Solutions Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Rare Disease Therapy Solutions Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Rare Disease Therapy Solutions Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Rare Disease Therapy Solutions Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Rare Disease Therapy Solutions Revenue Market Share by Type (2021-2032) Figure 22. Global Rare Disease Therapy Solutions Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Rare Disease Therapy Solutions Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Rare Disease Therapy Solutions Revenue Market Share by Application (2021-2032) Figure 25. North America Rare Disease Therapy Solutions Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Rare Disease Therapy Solutions Revenue Share by Type (2021-2032) Figure 27. North America Rare Disease Therapy Solutions Revenue Share by Application (2021-2032) Figure 28. North America Rare Disease Therapy Solutions Revenue Share by Country (2021-2032) Figure 29. United States Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Rare Disease Therapy Solutions Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Rare Disease Therapy Solutions Revenue Share by Type (2021-2032) Figure 34. Europe Rare Disease Therapy Solutions Revenue Share by Application (2021-2032) Figure 35. Europe Rare Disease Therapy Solutions Revenue Share by Country (2021-2032) Figure 36. Germany Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Rare Disease Therapy Solutions Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Rare Disease Therapy Solutions Revenue Share by Type (2021-2032) Figure 46. China Rare Disease Therapy Solutions Revenue Share by Application (2021-2032) Figure 47. Asia Rare Disease Therapy Solutions Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Rare Disease Therapy Solutions Revenue Share by Type (2021-2032) Figure 49. Asia Rare Disease Therapy Solutions Revenue Share by Application (2021-2032) Figure 50. Asia Rare Disease Therapy Solutions Revenue Share by Region (2021-2032) Figure 51. Japan Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Rare Disease Therapy Solutions Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Rare Disease Therapy Solutions Revenue Share by Type (2021-2032) Figure 59. SAMEA Rare Disease Therapy Solutions Revenue Share by Application (2021-2032) Figure 60. SAMEA Rare Disease Therapy Solutions Revenue Share by Country (2021-2032) Figure 61. Brazil Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Rare Disease Therapy Solutions Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Gene Therapy
  • Enzyme Replacement Therapy
  • Small Molecule Targeted Drugs
  • Cell Therapy
  • Others
Applications
  • Metabolic Diseases
  • Hematological Diseases
  • Others
Companies covered
  • Sarepta
  • Ultragenyx
  • Amicus Therapeutics
  • AOP Health
  • Fortrea
  • Chiesi Global Rare Diseases
  • Travere Therapeutics
  • Sobi
  • Novartis
  • Vertex Pharmaceuticals
  • Sarepta International UK Ltd.
  • Orsini
  • Roche
  • Certara
  • Sciensus

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Rare Disease Therapy Solutions Market by Type
  3. 1.2.1 Global Rare Disease Therapy Solutions Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Gene Therapy
  5. 1.2.3 Enzyme Replacement Therapy
  6. 1.2.4 Small Molecule Targeted Drugs
  7. 1.2.5 Cell Therapy
  8. 1.2.6 Others
  9. 1.3 Rare Disease Therapy Solutions Market by Application
  10. 1.3.1 Global Rare Disease Therapy Solutions Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Metabolic Diseases
  12. 1.3.3 Hematological Diseases
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Rare Disease Therapy Solutions Market Dynamics
  1. 2.1 Rare Disease Therapy Solutions Industry Trends
  2. 2.2 Rare Disease Therapy Solutions Industry Drivers
  3. 2.3 Rare Disease Therapy Solutions Industry Opportunities and Challenges
  4. 2.4 Rare Disease Therapy Solutions Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Rare Disease Therapy Solutions Market Perspective (2021-2032)
  2. 3.2 Global Rare Disease Therapy Solutions Growth Trends by Region
  3. 3.2.1 Global Rare Disease Therapy Solutions Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Rare Disease Therapy Solutions Market Size by Region (2021-2026)
  5. 3.2.3 Global Rare Disease Therapy Solutions Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Rare Disease Therapy Solutions Revenue by Players
  2. 4.1.1 Global Rare Disease Therapy Solutions Revenue by Players (2021-2026)
  3. 4.1.2 Global Rare Disease Therapy Solutions Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Rare Disease Therapy Solutions Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Rare Disease Therapy Solutions Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Rare Disease Therapy Solutions Key Players Headquarters & Area Served
  7. 4.4 Global Rare Disease Therapy Solutions Players, Product Type & Application
  8. 4.5 Global Rare Disease Therapy Solutions Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Rare Disease Therapy Solutions Market CR5 and HHI
  11. 4.6.3 2025 Rare Disease Therapy Solutions Tier 1, Tier 2, and Tier 3
5 Rare Disease Therapy Solutions Market Size by Type
  1. 5.1 Global Rare Disease Therapy Solutions Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Rare Disease Therapy Solutions Revenue by Type (2021-2032)
  3. 5.3 Global Rare Disease Therapy Solutions Revenue Market Share by Type (2021-2032)
6 Rare Disease Therapy Solutions Market Size by Application
  1. 6.1 Global Rare Disease Therapy Solutions Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Rare Disease Therapy Solutions Revenue by Application (2021-2032)
  3. 6.3 Global Rare Disease Therapy Solutions Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sarepta
  2. 7.1.1 Sarepta Company Information
  3. 7.1.2 Sarepta Business Overview
  4. 7.1.3 Sarepta Rare Disease Therapy Solutions Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sarepta Rare Disease Therapy Solutions Product Portfolio
  6. 7.1.5 Sarepta Recent Developments
  7. 7.2 Ultragenyx
  8. 7.2.1 Ultragenyx Company Information
  9. 7.2.2 Ultragenyx Business Overview
  10. 7.2.3 Ultragenyx Rare Disease Therapy Solutions Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Ultragenyx Rare Disease Therapy Solutions Product Portfolio
  12. 7.2.5 Ultragenyx Recent Developments
  13. 7.3 Amicus Therapeutics
  14. 7.3.1 Amicus Therapeutics Company Information
  15. 7.3.2 Amicus Therapeutics Business Overview
  16. 7.3.3 Amicus Therapeutics Rare Disease Therapy Solutions Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Amicus Therapeutics Rare Disease Therapy Solutions Product Portfolio
  18. 7.3.5 Amicus Therapeutics Recent Developments
  19. 7.4 AOP Health
  20. 7.4.1 AOP Health Company Information
  21. 7.4.2 AOP Health Business Overview
  22. 7.4.3 AOP Health Rare Disease Therapy Solutions Revenue and Gross Margin (2021-2026)
  23. 7.4.4 AOP Health Rare Disease Therapy Solutions Product Portfolio
  24. 7.4.5 AOP Health Recent Developments
  25. 7.5 Fortrea
  26. 7.5.1 Fortrea Company Information
  27. 7.5.2 Fortrea Business Overview
  28. 7.5.3 Fortrea Rare Disease Therapy Solutions Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Fortrea Rare Disease Therapy Solutions Product Portfolio
  30. 7.5.5 Fortrea Recent Developments
  31. 7.6 Chiesi Global Rare Diseases
  32. 7.6.1 Chiesi Global Rare Diseases Company Information
  33. 7.6.2 Chiesi Global Rare Diseases Business Overview
  34. 7.6.3 Chiesi Global Rare Diseases Rare Disease Therapy Solutions Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Chiesi Global Rare Diseases Rare Disease Therapy Solutions Product Portfolio
  36. 7.6.5 Chiesi Global Rare Diseases Recent Developments
  37. 7.7 Travere Therapeutics
  38. 7.7.1 Travere Therapeutics Company Information
  39. 7.7.2 Travere Therapeutics Business Overview
  40. 7.7.3 Travere Therapeutics Rare Disease Therapy Solutions Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Travere Therapeutics Rare Disease Therapy Solutions Product Portfolio
  42. 7.7.5 Travere Therapeutics Recent Developments
  43. 7.8 Sobi
  44. 7.8.1 Sobi Company Information
  45. 7.8.2 Sobi Business Overview
  46. 7.8.3 Sobi Rare Disease Therapy Solutions Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Sobi Rare Disease Therapy Solutions Product Portfolio
  48. 7.8.5 Sobi Recent Developments
  49. 7.9 Novartis
  50. 7.9.1 Novartis Company Information
  51. 7.9.2 Novartis Business Overview
  52. 7.9.3 Novartis Rare Disease Therapy Solutions Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Novartis Rare Disease Therapy Solutions Product Portfolio
  54. 7.9.5 Novartis Recent Developments
  55. 7.10 Vertex Pharmaceuticals
  56. 7.10.1 Vertex Pharmaceuticals Company Information
  57. 7.10.2 Vertex Pharmaceuticals Business Overview
  58. 7.10.3 Vertex Pharmaceuticals Rare Disease Therapy Solutions Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Vertex Pharmaceuticals Rare Disease Therapy Solutions Product Portfolio
  60. 7.10.5 Vertex Pharmaceuticals Recent Developments
  61. 7.11 Sarepta International UK Ltd.
  62. 7.11.1 Sarepta International UK Ltd. Company Information
  63. 7.11.2 Sarepta International UK Ltd. Business Overview
  64. 7.11.3 Sarepta International UK Ltd. Rare Disease Therapy Solutions Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Sarepta International UK Ltd. Rare Disease Therapy Solutions Product Portfolio
  66. 7.11.5 Sarepta International UK Ltd. Recent Developments
  67. 7.12 Orsini
  68. 7.12.1 Orsini Company Information
  69. 7.12.2 Orsini Business Overview
  70. 7.12.3 Orsini Rare Disease Therapy Solutions Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Orsini Rare Disease Therapy Solutions Product Portfolio
  72. 7.12.5 Orsini Recent Developments
  73. 7.13 Roche
  74. 7.13.1 Roche Company Information
  75. 7.13.2 Roche Business Overview
  76. 7.13.3 Roche Rare Disease Therapy Solutions Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Roche Rare Disease Therapy Solutions Product Portfolio
  78. 7.13.5 Roche Recent Developments
  79. 7.14 Certara
  80. 7.14.1 Certara Company Information
  81. 7.14.2 Certara Business Overview
  82. 7.14.3 Certara Rare Disease Therapy Solutions Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Certara Rare Disease Therapy Solutions Product Portfolio
  84. 7.14.5 Certara Recent Developments
  85. 7.15 Sciensus
  86. 7.15.1 Sciensus Company Information
  87. 7.15.2 Sciensus Business Overview
  88. 7.15.3 Sciensus Rare Disease Therapy Solutions Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Sciensus Rare Disease Therapy Solutions Product Portfolio
  90. 7.15.5 Sciensus Recent Developments
8 North America
  1. 8.1 North America Rare Disease Therapy Solutions Revenue (2021-2032)
  2. 8.2 North America Rare Disease Therapy Solutions Revenue by Type (2021-2032)
  3. 8.2.1 North America Rare Disease Therapy Solutions Revenue by Type (2021-2026)
  4. 8.2.2 North America Rare Disease Therapy Solutions Revenue by Type (2027-2032)
  5. 8.3 North America Rare Disease Therapy Solutions Revenue Share by Type (2021-2032)
  6. 8.4 North America Rare Disease Therapy Solutions Revenue by Application (2021-2032)
  7. 8.4.1 North America Rare Disease Therapy Solutions Revenue by Application (2021-2026)
  8. 8.4.2 North America Rare Disease Therapy Solutions Revenue by Application (2027-2032)
  9. 8.5 North America Rare Disease Therapy Solutions Revenue Share by Application (2021-2032)
  10. 8.6 North America Rare Disease Therapy Solutions Revenue by Country
  11. 8.6.1 North America Rare Disease Therapy Solutions Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Rare Disease Therapy Solutions Revenue by Country (2021-2026)
  13. 8.6.3 North America Rare Disease Therapy Solutions Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Rare Disease Therapy Solutions Revenue (2021-2032)
  2. 9.2 Europe Rare Disease Therapy Solutions Revenue by Type (2021-2032)
  3. 9.2.1 Europe Rare Disease Therapy Solutions Revenue by Type (2021-2026)
  4. 9.2.2 Europe Rare Disease Therapy Solutions Revenue by Type (2027-2032)
  5. 9.3 Europe Rare Disease Therapy Solutions Revenue Share by Type (2021-2032)
  6. 9.4 Europe Rare Disease Therapy Solutions Revenue by Application (2021-2032)
  7. 9.4.1 Europe Rare Disease Therapy Solutions Revenue by Application (2021-2026)
  8. 9.4.2 Europe Rare Disease Therapy Solutions Revenue by Application (2027-2032)
  9. 9.5 Europe Rare Disease Therapy Solutions Revenue Share by Application (2021-2032)
  10. 9.6 Europe Rare Disease Therapy Solutions Revenue by Country
  11. 9.6.1 Europe Rare Disease Therapy Solutions Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Rare Disease Therapy Solutions Revenue by Country (2021-2026)
  13. 9.6.3 Europe Rare Disease Therapy Solutions Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Rare Disease Therapy Solutions Revenue (2021-2032)
  2. 10.2 China Rare Disease Therapy Solutions Revenue by Type (2021-2032)
  3. 10.2.1 China Rare Disease Therapy Solutions Revenue by Type (2021-2026)
  4. 10.2.2 China Rare Disease Therapy Solutions Revenue by Type (2027-2032)
  5. 10.3 China Rare Disease Therapy Solutions Revenue Share by Type (2021-2032)
  6. 10.4 China Rare Disease Therapy Solutions Revenue by Application (2021-2032)
  7. 10.4.1 China Rare Disease Therapy Solutions Revenue by Application (2021-2026)
  8. 10.4.2 China Rare Disease Therapy Solutions Revenue by Application (2027-2032)
  9. 10.5 China Rare Disease Therapy Solutions Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Rare Disease Therapy Solutions Revenue (2021-2032)
  2. 11.2 Asia Rare Disease Therapy Solutions Revenue by Type (2021-2032)
  3. 11.2.1 Asia Rare Disease Therapy Solutions Revenue by Type (2021-2026)
  4. 11.2.2 Asia Rare Disease Therapy Solutions Revenue by Type (2027-2032)
  5. 11.3 Asia Rare Disease Therapy Solutions Revenue Share by Type (2021-2032)
  6. 11.4 Asia Rare Disease Therapy Solutions Revenue by Application (2021-2032)
  7. 11.4.1 Asia Rare Disease Therapy Solutions Revenue by Application (2021-2026)
  8. 11.4.2 Asia Rare Disease Therapy Solutions Revenue by Application (2027-2032)
  9. 11.5 Asia Rare Disease Therapy Solutions Revenue Share by Application (2021-2032)
  10. 11.6 Asia Rare Disease Therapy Solutions Revenue by Country
  11. 11.6.1 Asia Rare Disease Therapy Solutions Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Rare Disease Therapy Solutions Revenue by Country (2021-2026)
  13. 11.6.3 Asia Rare Disease Therapy Solutions Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Rare Disease Therapy Solutions Revenue (2021-2032)
  2. 12.2 SAMEA Rare Disease Therapy Solutions Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Rare Disease Therapy Solutions Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Rare Disease Therapy Solutions Revenue by Type (2027-2032)
  5. 12.3 SAMEA Rare Disease Therapy Solutions Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Rare Disease Therapy Solutions Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Rare Disease Therapy Solutions Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Rare Disease Therapy Solutions Revenue by Application (2027-2032)
  9. 12.5 SAMEA Rare Disease Therapy Solutions Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Rare Disease Therapy Solutions Revenue by Country
  11. 12.6.1 SAMEA Rare Disease Therapy Solutions Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Rare Disease Therapy Solutions Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Rare Disease Therapy Solutions Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst